MRM LC-MS Lung Cancer Protein Panel (Human)

The Biodesix Lung Cancer Protein Panel was developed using Multiple Reaction Monitoring Liquid Chromatography Mass Spectrometry (MRM LC-MS) which focuses on quantifying predefined sets of proteins with high sensitivity and reproducibility. Changes in composition of proteins within the circulating proteome can be correlated to disease or therapy response.

While genomic data uncovers the potential genetic drivers of cancer (tumor), proteomic data profiles the patient's (host) immune response to the cancer. Both are critical elements for interpreting the real-time complexity of the cancer disease state (cancer ecosystem).

371 Protein MRM LC-MS Lung Cancer Panel Targets

1433B	BASP1	CEAM8	DEFB1	F10A1	GELS	HYOU1	KLK13	MLH1	NGLY1	PLAC1	RAP2B	SSRD	TNF12
1433E	BAX	CERU	DESP	FAM3C	GGH	IBP2	KLK14	MMP1	NHRF1	PLACL	RAP2C	STAT1	TNR6
1433S	BDNF	CH10	DFB4A	FAS	GPC3	IBP3	KLK6	MMP11	NIBAN	PLIN2	RCN3	STAT3	TPIS
1433T	BGH3	CH60	DHI1L	FCGR1	GRAN	ICAM1	KNG1	MMP12	NMU	PLIN3	RL24	STC1	TRFL
1433Z	BMP2	CKAP4	DMBT1	FGF10	GREB1	ICAM3	KPYM	MMP14	NRP1	PLOD1	S10A1	STT3A	TSP1
6PGD	BST1	CL041	DMKN	FGF2	GREM1	IDHP	KRT35	MMP2	ODAM	PLOD2	S10A6	TAGL	TTHY
A1AG1	C163A	CLCA1	DPP4	FGF7	GRP	IF4A1	LAMB2	MMP26	OSTP	PLSL	S10A7	TARA	TYPH
ABCD1	C4BPA	CLIC1	DSG2	FGF9	GRP78	IGF1	LDHA	MMP7	OVOS2	PLUNC	SAA	TBA1B	UGGG1
ADA12	CAH9	CLUS	DX39A	FGFR2	GSLG1	IKIP	LDHB	MMP9	P5CS	PLXB3	SCF	TBB2A	UGGG2
ADML	CALR	CMGA	DX39B	FGFR3	GSTP1	IL18	LEG1	MOGS	PA2GX	PLXC1	SDC1	TBB3	UGPA
AGR2	CALU	CNTN1	DYRK2	FGL2	GTR1	IL19	LEG3	MPRI	PAPP1	POSTN	SEM3G	TBB5	UPAR
AIFM1	CALX	CO4A1	EDN2	FHIT	GTR3	IL22	LEG9	MRP3	PBIP1	PPAL	SEPR	TCPA	UTER
ALDOA	CAP7	CO5A2	EF1A1	FIBA	H2A1	IL32	LG3BP	MUC1	PCBP1	PPBT	SERPH	TCPD	VA0D1
AMPN	CATB	CO6A3	EF1D	FINC	H2A1B	IL7	LPLC3	MUC16	PCBP2	PPIB	SFPA2	TCPQ	VAV3
ANGP1	CATG	COCA1	EF2	FKB11	H2A1C	IL8	LPLC4	MUC4	PCD15	PRDX1	SFTA1	TCPZ	VEGFA
ANGP2	CBPB2	COF1	EGF	FOLH1	H2A1D	ILEU	LPPRC	MUC5B	PCNA	PRDX4	SG3A2	TDRD3	VEGFC
APOA1	CCL22	COIA1	EGFL6	FOLR1	HG2A	ILK	LRP1	MUCL1	PCYOX	PROF1	SGPL1	TENA	VEGFD
APOE	CD14	COX5A	ENOA	FOXA2	HGF	INHBA	LUM	NAMPT	PDGFA	PRP31	SIAL	TENX	VGFR1
ASM3B	CD24	CRP	ENOG	FP100	HMGA1	ISLR	LY6K	NAPSA	PDGFB	PRS6A	SLPI	TERA	VTNC
AT2A2	CD2A2	CS051	ENOX2	FRIH	HPRT	ITA5	LYAM2	NCF4	PDGFD	PSCA	SMD3	TETN	VWC2
ATS1	CD38	CSF1	ENPL	FRIL	HPSE	ITAM	LYAM3	NDKA	PDIA3	PTGIS	SMS	TF	WNT3A
ATS12	CD40L	CSF2	EPHB6	G3P	HPT	K0090	LYOX	NDKB	PDIA4	PTPA	SODM	TFR1	WT1
ATS19	CD44	CT085	EPOR	G6PD	HS90A	K1C18	LYPD3	NDUS1	PDIA6	PTPRC	SORL	TGFA	ZA2G
BAGE1	CD59	CTGF	ERBB3	G6PI	HS90B	K1C19	MAGA4	NEBL	PECA1	PTPRJ	SPB3	THAS	ZG16B
BAGE2	CD97	CYR61	EREG	GA2L1	HSPB1	K2C8	MASP1	NEK4	PEDF	PVR	SPB5	THY1	
BAGE3	CDCP1	CYTA	ERO1A	GALT2	HTRA1	KIT	MDHC	NET1	PERM	RAB32	SPON2	TIMP1	
BAGE4	CDK4	CYTB	ESM1	GAS6	HXK1	KITH	MDHM	NEU2	PERP1	RAGE	SPRC	TIMP3	
BAGE5	CEAM5	DDX17	EZRI	GDIR2	HYAL2	KLK11	MIF	NGAL	PGAM1	RAN	SRC	TLL1	

Biodesix is pleased to offer custom panels as well as custom assay development for new targets.

Contact us to learn how Biodesix can support your program: bizdev@biodesix.com

About Biodesix

Biodesix is a lung cancer diagnostic solutions company addressing the continuum of patient care from early diagnosis of lung nodules through late stage cancer. The company develops diagnostic tests addressing important clinical questions by combining simple blood draws and multi-omics with the power of artificial intelligence. Biodesix is the first company to offer three best-in class tests for patients with lung cancer, and multiple pipeline tests including one with the potential to identify patients who may benefit from immunotherapies. The Biodesix Lung Reflex® strategy integrates the GeneStrat® and VeriStrat® tests to support treatment decisions with results in 72 hours. The Nodify XL2™ and EarlyCDT Lung® nodule tests, evaluate the risk of malignancy, enabling physicians to triage patients to the most appropriate course of action. Biodesix also partners with the world's leading biotechnology and pharmaceutical companies to solve complex diagnostic challenges. For more information about Biodesix, please visit www.biodesix.com.